Cvs Health Corp (CVS) Stock Price & Analysis
Cvs Health Corp (CVS) fell 0.02% to USD 97.06 as of June 9, 2026 at 22:36 UTC, according to Nexqual real-time market data.
CVS last closed at USD 97.08; the session ranged USD 95.95–97.52 on volume of 4,990,894 shares. Market capitalization is $123.84B, with a 52-week range of USD 58.5–98.43 (NYQ). Source: Nexqual, June 9, 2026 at 22:36 UTC.
Key Statistics (as of June 9, 2026 at 22:36 UTC)
| Price | USD 97.06 |
|---|---|
| Change | ▼ 0.02% (down) |
| Previous Close | USD 97.08 |
| Open | USD 96.7 |
| Day Range | USD 95.95 – 97.52 |
| 52-Week Range | USD 58.5 – 98.43 |
| Volume | 4,990,894 shares |
| Market Cap | $123.84B |
| Exchange | NYQ |
Technical Analysis (CVS)
Nexqual's technical model rates CVS "BUY" based on 5 bullish and 1 bearish signals across 124 daily candles, as of June 9, 2026 at 22:36 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 69.34 (neutral) |
| vs SMA50 | Above (USD 85.12) |
| MACD | 2.64 (positive) |
Analyst Ratings (CVS)
Wall Street analysts rate CVS "Strong Buy" based on 26 analysts, with a mean price target of USD 103.81 (range USD 79–140), per Nexqual as of June 9, 2026 at 22:36 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 26 |
| Mean Target | USD 103.81 |
| High Target | USD 140 |
| Low Target | USD 79 |
| Buy / Hold / Sell | 24 / 4 / 0 |
Earnings (CVS)
| Next Earnings Date | 2026-07-30 |
|---|---|
| EPS Estimate | USD 1.83 |
| Revenue Estimate | $100.09B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 2.57 vs est 2.21 ▲ beat |
| 2025-12-31 | USD 1.09 vs est 1 ▲ beat |
| 2025-09-30 | USD 1.6 vs est 1.36 ▲ beat |
| 2025-06-30 | USD 1.81 vs est 1.46 ▲ beat |
Source: Nexqual, June 9, 2026 at 22:36 UTC.
Financials & Fundamentals (CVS)
| Total Revenue | $405.62B |
|---|---|
| Revenue Growth (YoY) | +6.10% |
| Gross Margin | +13.39% |
| Operating Margin | +4.12% |
| Profit Margin | +0.72% |
| ROE | +3.75% |
| Debt / Equity | 100.91 |
| Current Ratio | 0.87 |
| Total Cash | $11.80B |
| Total Debt | $78.35B |
| Free Cash Flow | $5.20B |
Source: Nexqual, June 9, 2026 at 22:36 UTC.
Financial Health Score (CVS)
Nexqual rates Cvs Health Corp's overall financial health "Weak" across five dimensions, as of June 9, 2026 at 22:36 UTC.
| Growth | Solid — Revenue +8% YoY (annual) |
|---|---|
| Profitability | Weak — Gross margin 13%, operating 4% |
| Balance Sheet | Weak — $11.8B cash vs $78.3B debt |
| Cash Flow | Mixed — FCF $5.20B, slim 1.3% margin |
| Efficiency | Weak — ROE 4%, ROA 2.7% |
Ownership (CVS)
| Insider Ownership | +0.06% |
|---|---|
| Institutional Ownership | +90.01% |
| Shares Outstanding | 1.28B |
| Float | 1.27B |
| Short % of Float | +1.54% |
Source: Nexqual, June 9, 2026 at 22:36 UTC.
Leadership (CVS)
Cvs Health Corp is led by J. David Joyner CEBS (age 60), CEO, President & Chairman, per Nexqual as of June 9, 2026 at 22:36 UTC.
| CEO, President & Chairman | J. David Joyner CEBS (age 60) |
|---|---|
| Executive VP & CFO | Brian O. Newman (age 56) |
| Executive VP & Group President | Prem S. Shah Pharm.D (age 45) |
| Executive VP & President of Aetna | Steven Hale Nelson (age 66) |
| Executive Vice President, Corporate Services & Chief Legal Officer | Samrat S. Khichi (age 58) |
Major Backers & Investors (CVS)
Notable institutional backers of Cvs Health Corp include Dodge & Cox Inc., Capital Group, WASHINGTON MUTUAL INVESTORS FUND, according to Nexqual as of June 9, 2026 at 22:36 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Dodge & Cox Inc. | 6.72% |
| Capital Group | 6.05% |
| WASHINGTON MUTUAL INVESTORS FUND | 2.49% |
| FMR, LLC | 2.45% |
| JPMorgan | 2.31% |
| Invesco | 1.97% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 15.14% |
| BlackRock | 11.16% |
| State Street | 5.84% |
| Geode Capital | 2.31% |
Source: Nexqual, June 9, 2026 at 22:36 UTC.
From Cvs Health Corp's Latest SEC 10-K Filing (filed 2026-02-10)
Key Strengths & Strategy (as disclosed to the SEC)
- We serve an estimated more than 37 million people through traditional, voluntary and consumer-directed health insurance products and related services, including expanding Medicare Advantage offerings and a leading standalone Medicare Part D prescription drug plan ("PDP").
- Retail Pharmacy Network Management Services The Company maintains a national network of approximately 63,000 retail pharmacies, consisting of approximately 34,500 chain pharmacies (which include CVS pharmacy locations) and approximately 28,500 independent pharmacies, in the U.S., including Puerto Rico, the District of Columbia, Guam and the U.S.
- During the year ended December 31, 2025, the Company performed more than 3.5 million IHEs. 9 While in the home, providers perform IHEs with the assistance of the Company's longitudinal patient records and proprietary clinical workflow software with its integrated device hub.
- The Health Engagement Engine ® technology and proprietary clinical algorithms help connect various parts of the enterprise and serve an essential role in cost management and health improvement, leveraging cloud-native technologies and practices.
Partnerships
- Under Duals contracts, the rate setting process is generally established by CMS in partnership with the state government agency participating in the demonstration project.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ABBV | AbbVie Inc. | USD 225.42 | ▼ 0.8% |
| TGT | Target Corporation | USD 126.61 | ▲ 3.3% |
| BMY | Bristol-Myers Squibb Company | USD 56.48 | ▼ 1.38% |
| UNH | UnitedHealth Group Incorporated | USD 413 | ▲ 3.39% |
| ABT | Abbott Laboratories | USD 91.25 | ▲ 0.2% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 22:36 UTC. This page is informational and not investment advice.